UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Medytox, Daewoong still in dispute over Nabota's spore appraisal
Medytox and Daewoong Pharmaceutical continued to brawl over the origin of t...
by Lee Han-soo
|
2019-10-15 11:28
라인
Kolon Life Science shares surge after TissueGene’s survival
Shares of Kolon Life Science shot up after the regulator decided to delay t...
by Jeong Sae-im
|
2019-10-14 18:01
라인
Lilly’s Taltz shows superiority to Tremfya in treating psoriasis patients
The Korean branch of Eli Lilly said it has presented the phase 4 IXORA-R st...
by Lee Han-soo
|
2019-10-14 18:01
라인
First lung disease reported here with suspected ties to vaping
The Korea Centers for Disease Control and Prevention (KCDC) said that it ha...
by Lee Han-soo
|
2019-10-14 18:01
라인
HLB merges with Elevar to own rivoceranib rights
HLB said it would merge with its subsidiary Elevar, a U.S.-based developer ...
by Jeong Sae-im
|
2019-10-14 14:43
라인
HanAll's Chinese partner ends P2 trial of dry eye treatment
HanAll Biopharma said that Harbour Biomed, its Chinese partner, has complet...
by Lee Han-soo
|
2019-10-14 14:08
라인
[Special] How are Korean employees coping with big-pharma M&As?
Since multinational pharmaceutical companies announced merger and acquisiti...
by Kim Yun-mi
|
2019-10-14 13:45
라인
Sanofi releases data showing improved survival for prostate cancer treatment
Sanofi said that it has published research results confirming a longer radi...
by Lee Han-soo
|
2019-10-14 12:16
라인
Regulator keeps Kolon Tissuegene listed with 1-year grace period
The Korean Exchange (KRX) decided to keep Kolon Tissuegene listed on the Ko...
by Lee Han-soo
|
2019-10-12 09:41
라인
GC to market Merck's diabetes treatment
Merck Biopharma Korea said that GC would market Glucophage, its diabetes tr...
by Lee Han-soo
|
2019-10-11 18:13
라인
Bayer drugs out of stock in Korea
Bayer is having trouble supplying its drug in the local market as the compa...
by Lee Han-soo
|
2019-10-11 16:36
라인
Drug regulator to hire 87 more reviewers next year
The Ministry of Food and Drug Safety said it would add 87 staff for the rev...
by Lee Hye-seon
|
2019-10-11 16:35
라인
Sanofi to cover part of Dupixent cost for atopic dermatitis patients
Sanofi said it would run a program to support part of the cost of Dupixent,...
by Kim Yun-mi
|
2019-10-11 15:13
라인
‘Direct-to-consumer genetic testing needs preparation’
The government has decided to deregulate direct-to-consumer (DTC) genetic t...
by Kim Eun-young
|
2019-10-11 15:12
라인
Takeda Korea’s labor union goes on strike
The conflict between Takeda Korea's management and labor union has reac...
by Lee Han-soo
|
2019-10-11 14:33
라인
Roche’s Tecentriq combo therapy shows encouraging results
Roche Korea said the company had presented results from a phase 1b study ev...
by Lee Han-soo
|
2019-10-10 17:36
라인
Yuyu confirms safety of its antiplatelet drug
Yuyu Pharmaceutical said that it has confirmed the safety of Yuclid (ingred...
by Lee Han-soo
|
2019-10-10 17:35
라인
ICDM 2019 to host 3-day meet in Seoul
The 2019 International Congress of Diabetes and Metabolism will kick off it...
by Lee Han-soo
|
2019-10-10 16:02
라인
Doctors call Boehringer Ingelheim’s Jardiance marketing ‘unethical’
The medical community criticized Boehringer Ingelheim Korea’s recent releas...
by Kim Yun-mi
|
2019-10-10 16:01
라인
Researchers use lung cancer organoid to select best drug for patients
An Asan Medical Center research team has developed an organoid culture tech...
by Lee Han-soo
|
2019-10-10 16:00
-
이전
91
92
93
94
95
96
97
98
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top